S6G5T-3 in Acne Vulgaris

Phase 3, randomised, double-blind trial of benzoyl peroxide + sulfur and tretinoin in acne vulgaris, sponsored by Sol-Gel Technologies. Primary endpoints: Percentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of Clear or Almost Clear and a Score ≥2 Grades Less Than Baseline at 12 weeks and Change From Baseline in Inflammatory Lesion Counts on the Face at Week 12. Started Dec 2018; status: completed.